Case report: A case of ITP-like thrombocytopenia induced by denosumab

Denosumab has been widely utilized in the management of osteoporosis; however, thrombocytopenia as an adverse reaction associated with denosumab has been infrequently reported, and its underlying mechanism is not yet fully understood. We present a retrospective analysis of a rare case of suspected immune-mediated thrombocytopenia resembling immune thrombocytopenia (ITP) in a patient with primary osteoporosis following denosumab treatment, along with a comprehensive review of the relevant literature to investigate the potential mechanisms of denosumab-induced ITP-like thrombocytopenia. This case underscores the need for routine platelet monitoring during clinical use of denosumab and serves as a pharmacovigilance signal, providing a basis for future drug safety assessments.